Navigation Links
GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg)

LONDON & EXTON, Pa.--(BUSINESS WIRE)--Apr 9, 2007 - GlaxoSmithKline (LSE and NYSE:GSK) and Adolor Corporation (Nasdaq:ADLR) today announced data from Study 767905/014 and provided an update on the clinical development program for alvimopan (Entereg/Entrareg(R)).

Study 014, a Phase 3, double blind, placebo-controlled (12 month) study, was designed to evaluate the long-term safety and tolerability of alvimopan 0.5 mg twice daily in patients taking opioids for chronic non-cancer pain and experiencing opioid-induced bowel dysfunction (OBD). A total of 805 patients were enrolled into the study and randomized 2:1; a total of 538 patients received alvimopan and 267 received placebo.

Consistent with findings from previous studies the most common adverse events observed in Study 014 were those affecting the gastrointestinal (GI) tract, including abdominal pain and diarrhea. The incidence of GI adverse events observed was similar between patients treated with alvimopan (40%) and placebo (35%).

While the proportion of patients experiencing serious adverse events was similar between those treated with alvimopan (13%) and placebo (11%), a numerical imbalance was observed in the number of cardiovascular (CV) and neoplasm cases categorized as serious adverse events among alvimopan-treated patients.

Preliminary findings from Study 014 are outlined below, together with information regarding actions taken by GSK and Adolor regarding the two ongoing alvimopan studies.

Cardiovascular Adverse Events

Results from a six-month interim analysis of Study 014, previously announced in November 2006, showed an increase which was not statistically significant in the reported incidence of serious CV adverse events in patients receiving alvimopan relative to placebo. Results from completed Study 014 showed an increase in myocardial infarctions and all CV SAEs reported by patients treated with alvimopan c
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:8/28/2014)... According to a new market ... Market (Tags, Readers, Middleware, Printers and Cabinets) - Global ... - 2020" the global radiofrequency identification (RFID) market was ... expected to grow at a CAGR of 13.9% from ... USD 5.3 billion in 2020. Browse the ...
(Date:8/28/2014)... , Aug. 28, 2014  In recognition of ... health complications from the flu, pneumonia, shingles and ... have declared September to be Senior Vaccination ... age, it is important that adults ages 65 ... their vaccinations. CVS pharmacists and MinuteClinic nurse practitioners ...
(Date:8/28/2014)... CASTLE ROCK, Colo. , Aug. 28, 2014 /PRNewswire/ ... diagnostic company focused on obtaining FDA clearance for ... a rapid blood test for aiding in identifying children, ... who are at low risk for appendicitis, today announced ... Rodman & Renshaw 16 th Annual Global Investment ...
Breaking Medicine Technology:Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 2Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 3Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 4Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 5September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 2September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 3September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 4Venaxis to Present at September Investor Conferences 2Venaxis to Present at September Investor Conferences 3
(Date:8/28/2014)... Recently, iFitDress.com, the popular online supplier of wedding dresses ... range of fashionable bridesmaid dresses . Along with that, ... are offered with big discounts, from 15 to 65 percent ... 16. , The company’s experienced workers never compromise on ... all its products are trendy and graceful. , “We are ...
(Date:8/28/2014)... Lake Worth, FL (PRWEB) August 28, 2014 ... of drug use affecting users in the workplace. A ... and Drug Dependence (NCADD) states that drug abuse ... , Employees who use or are addicted to drugs ... Drug users’ activities carry over into the workplace, causing ...
(Date:8/28/2014)... 2014 ABC television stars will join ... Show of Strength Telethon airing Sunday, Aug. 31, 9/8c ... raise funds and awareness to help save and improve ... disease. , Viewers tuning into the 2014 telethon to ... and introductions from some of the network’s leading stars, ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Kirklyn Smith, an ... what may be a new world’s record by walking 5,000 ... TrekDesk we are constantly amazed by the thousands of individual ... some just seem to stand out more than the others. ... 24 hour step count which tallies a range of 54,823 ...
(Date:8/28/2014)... Amy Norton HealthDay Reporter ... that sending electrical currents through the scalp to a specific ... to a day. In a small study of healthy ... up certain networks involved in memory. That, in turn, boosted ... hours after the brain stimulation. During TMS, an electromagnetic ...
Breaking Medicine News(10 mins):Health News:Fashionable Bridesmaid Dresses for Autumn 2014 from iFitDress.com 2Health News:Drug Use Causes Problems in the Workplace 2Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 2Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 3Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 4Health News:There are many reasons why Americans' exercise levels have declined - Meet an executive that refuses to sit still with his TrekDesk Treadmill Desk even in a sedentary job 2Health News:Electrical Pulses to Scalp May Boost Memory: Study 2Health News:Electrical Pulses to Scalp May Boost Memory: Study 3
... or refused early childhood immunizations , TUESDAY, May 4 ... vaccines for their very young children in 2008, and 12 ... them more vulnerable to illness, a new study shows. , ... by the time they,re 2 years old are at risk ...
... University have found that colonoscopy preparation drugs administered the ... those given the night before and the morning of ... effects such as abdominal pain, sleep loss and workday ... results between 116 colonoscopy patients given a split dosage ...
... ... debt resolution provider while more accurately reflecting its strengths and abilities , ... Baltimore, MD (PRWEB) May 4, ... businesses across America, is pleased to announce the completion of its rebranding, establishing itself ...
... that a key protein called PEA-15 stops T-cell proliferation by ... proliferation is essential in preventing certain blood cancers and autoimmune ... to infection. Findings of the study are reported in ... a publication of The Federation of American Societies for Experimental ...
... TCT for Surgeons will showcase the expansion of hybrid ... improving outcomes for patients undergoing cardiac surgery. Now in ... Cardiovascular Therapeutics (TCT) 2010 (September 21-25), the annual scientific ... will drive forward the growing collaboration among interventional cardiologists ...
... in U.S. ,stroke belt, are among least informed, survey ... is a leading cause of death in the United ... that nearly 60 percent don,t known if their local ... efforts, "the public seems less aware of stroke-certified hospitals," ...
Cached Medicine News:Health News:Misinformation About Vaccine Safety Puts Kids at Risk of Illness 2Health News:Study finds cutting colonoscopy preparation from 2 days to 1 day just as effective 2Health News:Nationwide Tax Solutions Rebrands Itself as Tax Strategies 2Health News:Study finds key protein controls T-cell proliferation 2Health News:Many Unaware of Local Stroke Centers 2
Black multi-pinhole occluder...
6 inch hand held occlcuder with 49 holes...
Designed to provide occlusion while permitting observation of the eye. Helpful to determine if only one eye is deviating. Approximately 9 inches long....
Manual Lensmeter....
Medicine Products: